Imbio Funding: How Much Did They Raise & Key Investors

How Much Did Imbio Raise?
Funding & Key Investors

Imbio has solidified its position in the healthcare technology sector by securing a total capital infusion of $2.7M. This trajectory of financial backing, which includes a recent strategic investment of $150K, underscores the market confidence in the company's ability to revolutionize diagnostic workflows. By leveraging advanced computational intelligence, the firm continues to attract significant interest from institutional partners focused on the intersection of medical imaging and scalable software solutions.

The company's growth narrative is defined by a series of strategic financing rounds, beginning with private equity support in 2015, followed by a substantial Series A round in 2017, and culminating in a debt financing arrangement in 2020. This progression reflects a mature approach to capital management, enabling the firm to transition from early-stage research and development into a robust enterprise-level provider of clinical decision support tools.

What is Imbio?

Imbio

Software

Healthcare Software

Business Services

Imbio specializes in AI-driven medical imaging analysis, specifically targeting complex lung and cardiothoracic conditions. By integrating sophisticated algorithms for lung density, texture analysis, and coronary calcification, the company provides physicians and health systems with actionable insights that facilitate personalized medicine. Their platform is designed for interoperability and secure deployment, ensuring that diagnostic precision is maintained across diverse clinical environments. Through strategic collaborations with pharmaceutical and medical device manufacturers, Imbio is effectively bridging the gap between raw imaging data and disease-specific therapeutic interventions, thereby enhancing patient management outcomes on a global scale.

How much funding has Imbio raised?

Imbio has raised a total of $2.7M across 3 funding rounds:

2015

Private Equity

$1.1M

2017

Series A

$1.5M

2020

Debt

$150K

Private Equity (2015): $1.1M, investors not publicly disclosed

Series A (2017): $1.5M led by Invenshure

Debt (2020): $150K supported by PPP

Key Investors in Imbio

Invenshure

Invenshure is a venture firm dedicated to transforming institutional intellectual property into successful commercial ventures through a focus on early-stage development.

PPP

Public-Private Partnership

Private Equity Firm

Undisclosed investor participating in the funding round.

What's next for Imbio?

With the recent infusion of $150K, Imbio is well-positioned to accelerate its product roadmap and expand its footprint within the global healthcare ecosystem. The strategic focus will likely shift toward deepening the integration of its diagnostic algorithms into existing hospital infrastructure and expanding its portfolio of custom imaging solutions for pharmaceutical partners. As the demand for automated, high-fidelity diagnostic tools continues to rise, Imbio's commitment to scalable, interoperable technology will be critical in maintaining its competitive advantage. Future growth will likely be driven by the continued refinement of its AI models and the pursuit of new clinical applications that address unmet needs in cardiothoracic care.

See full Imbio company page

See More Financial Insights